ConductScience.org, home

Comparison · NCT01495481-f14157f8

Dexmedetomidine vs Adenosine: Number of Participants With Tachyarrhythmias After Medication Administration

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dexmedetomidine vs Adenosine: Number of Participants With Tachyarrhythmias After Medication Administration. Trial comparisons, record NCT01495481-f14157f8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01495481-f14157f8

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.149wilson
Risk in group 2000.149wilson
Risk difference, group 1 minus group 20-0.1490.149newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DexmedetomidinePatients will receive dexmedetomidine for the termination of supraventricular tachycardia (SVT)~Dexmedetomidine: Dexmedetomidine 1 mcg/kg, Intravenous push022OG000
Group 2Adenosine
Patients will receive Adenosine for the termination of SVT~Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
022OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Tachyarrhythmias After Medication Administration
Description
Number of participants with tachyarrhythmias, including Ventricular (Ventricular Tachycardia \& Fibrillation)and supraventricular (Atrial Flutter \& Fibrillation) after dexmedetomidine vs. adenosine administration
Time frame
10 minutes
Population

Source ClinicalTrials.gov

Trial

Title
Dexmedetomidine and Adenosine: Therapeutic Use for SVT
NCT number
NCT01495481
Phases
NA
Conditions
Supraventricular Tachycardia
Interventions
Dexmedetomidine, Adenosine
Lead sponsor
University of Pittsburgh
Results first posted
2017-03-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01495481-f14157f8